ClinicalTrials.gg
CompletedNCT01933334LOTUSSUpdated Aug 4, 2016Results posted

Safety and Tolerability of Pirfenidone in Participants With Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) (LOTUSS)

A Phase 2 interventional study of Pirfenidone in Systemic Sclerosis, sponsored by Genentech, Inc.. Completed at 22 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-08-04.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 165 studies in Scleroderma, Systemic with a site in United States — 40 open to participants now, 52 under way, 6 of them phase 3. Scleroderma, Systemic · United States.

Enrollment
50th of 142
63 · median 34
Started
2013
with 3 others
Phase 2
54 of 165
10 open now
Registered
60th of 165
by date

Among the 165 studies in Scleroderma, Systemic with a site in United States, this one is the 50th largest by enrollment of the 142 interventional ones that give a count, is one of 4 that started in 2013, is one of 54 in phase 2, and was the 60th registered.

Scleroderma, Systemic

613 studies on the registry are indexed under Scleroderma, Systemic; 221 are open to participants now.

Browse Scleroderma, Systemic studies →

Open to participants now

40 of the 165 studies in Scleroderma, Systemic with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 145 Scleroderma, Systemic studies recruiting now, 83 (57%) set no upper age limit and 49 (34%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 165 studies in Scleroderma, Systemic with a site in United States, or all of them as a file.
02

Study summary

PSSc-001 (LOTUSS)

This study is a Phase 2, multinational, open-label, randomized, parallel-group, safety and tolerability study of pirfenidone in participants with systemic sclerosis-related interstitial lung disease (SSc-ILD).

03

Conditions studied

  • Systemic Sclerosis

Keywords

  • pirfenidone
  • SSc-ILD
  • scleroderma
  • systemic sclerosis
  • interstitial lung disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of systemic sclerosis-related (SSc) confirmed by the American College of Rheumatology classification criteria of systemic sclerosis (Masi 1980); duration of diagnosis less than (\<) 7 years
  2. Diagnosis of SSc-ILD based on an high-resolution computed tomography (HRCT) scan
  3. Screening forced vital capacity (FVC) greater than equal to (>=) 50 percent (%) of the predicted value, and screening carbon monoxide diffusing capacity (DLCO) >=40% of the predicted value
  4. At study entry, the participant either was not taking SSc-ILD medication or was taking cyclophosphamide or mycophenolate

Exclusion criteria

Exclusion Criteria:

  1. pulmonary hypertension
  2. Known underlying liver disease
  3. Clinical evidence of significant aspiration or uncontrolled gastroesophageal reflux
  4. History of clinically significant asthma or
  5. Active infection
  6. Diagnosis of another connective tissue disorder
  7. Evidence of a that is likely to result in significant disability or require significant medical or surgical intervention
  8. History of unstable or deteriorating cardiac or pulmonary disease (other than SSc-ILD)
  9. Pregnancy or lactation
  10. \<40 milliliters per minute (mL/min)
  11. Prior use of pirfenidone
  12. Unsuitable for enrollment or unlikely to comply with study requirements
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    Pirfenidone: 4-Week Titration Group

    Participants will receive one 267 milligrams (mg) oral pirfenidone capsule three times daily (TID) (801 mg per day \[mg/day\]) for 2 weeks followed by two 267 mg oral pirfenidone capsules TID (1602 mg/day) for 2 weeks (titration period) and then three 267 mg oral pirfenidone capsules TID (2403 mg/day) for 12 weeks maintenance period).

    Drug: Pirfenidone

  • Experimental
    Pirfenidone: 2-Week Titration Group

    Participants will receive one 267 mg oral pirfenidone capsule TID (801 mg/day) for 1 week followed by two 267 mg oral pirfenidone capsules TID (1602 mg/day) for 1 week (titration period) and then three 267 mg oral pirfenidone capsules TID (2403 mg/day) for 14 weeks (maintenance period).

    Drug: Pirfenidone

Interventions

  • Pirfenidone will be administered orally at a dose of 267 mg one oral capsule TID (801 mg/day) for 1 or 2 weeks followed by two 267 mg oral capsules TID (1602 mg/day) for 1 or 2 weeks (titration period) and then three 267 mg oral capsules TID (2403 mg/day) for 12 weeks (maintenance period).

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment-Emergent Adverse Events (AEs)

    Percentage of participants who had treatment-emergent AEs, defined as newly occurring or worsening after first dose. Relatedness to (study drug) was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.

    Time frame: From baseline up to 28 days after the last dose of study drug (last dose = Week 16)

  2. Percentage of Participants With Treatment-Emergent Serious Adverse Events (SAEs)

    An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: From baseline up to 28 days after the last dose of study drug (last dose = Week 16)

Secondary outcomes

  1. University of California at Los Angeles (UCLA) Scleroderma Clinical Trial Consortium (SCTC) Gastrointestinal Trial (GIT) Questionnaire Scale Scores

    UCLA SCTC GIT Scale 2.0 is a 34-item self-administered questionnaire to obtain participant's assessment of the frequency of GI symptoms in preceding 7 days and how symptoms affected his/her life. All but 2 items were scored on a 0 to 3 scale (0=better health, 3=worse health); remaining 2 items were scored as 0 (better health) and 1 (worse health). The 34 items are divided into seven scales (reflux, distention/bloating, fecal soilage, diarrhea, social functioning, emotional well-being, and constipation). Individual scale score was calculated as the average of the items in the scale. Individual scale score ranged from 0 to 3 for reflux, distention/bloating, fecal soilage, social functioning, and emotional well-being; 0 to 2 for diarrhea; and 0 to 2.5 for constipation. A total score was also calculated as the average of 6 of the 7 scales (omitting constipation) and ranged from 0 to 2.83. For individual and total scores 0 indicated better health and higher score indicates worse health.

    Time frame: Baseline, Weeks 4, 8, 12, and 16

07

Results

Posted Sep 28, 2015

Participant flow

Participant flow — Overall Study
MilestonePirfenidone: 2-Week Titration GroupPirfenidone: 4-Week Titration Group
Started3231
Completed2729
Not completed52
Withdrew: Adverse event51
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryPercentage of Participants With Treatment-Emergent Adverse Events (AEs)

Percentage of participants who had treatment-emergent AEs, defined as newly occurring or worsening after first dose. Relatedness to (study drug) was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.

Time frame:
From baseline up to 28 days after the last dose of study drug (last dose = Week 16)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-Emergent Adverse Events (AEs)
percentage of participantsPirfenidone: 2-Week Titration GroupPirfenidone: 4-Week Titration Group
Percentage of Participants With Treatment-Emergent Adverse Events (AEs)96.996.8
PrimaryPercentage of Participants With Treatment-Emergent Serious Adverse Events (SAEs)

An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

Time frame:
From baseline up to 28 days after the last dose of study drug (last dose = Week 16)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-Emergent Serious Adverse Events (SAEs)
percentage of participantsPirfenidone: 2-Week Titration GroupPirfenidone: 4-Week Titration Group
Percentage of Participants With Treatment-Emergent Serious Adverse Events (SAEs)9.40.0
SecondaryUniversity of California at Los Angeles (UCLA) Scleroderma Clinical Trial Consortium (SCTC) Gastrointestinal Trial (GIT) Questionnaire Scale Scores

UCLA SCTC GIT Scale 2.0 is a 34-item self-administered questionnaire to obtain participant's assessment of the frequency of GI symptoms in preceding 7 days and how symptoms affected his/her life. All but 2 items were scored on a 0 to 3 scale (0=better health, 3=worse health); remaining 2 items were scored as 0 (better health) and 1 (worse health). The 34 items are divided into seven scales (reflux, distention/bloating, fecal soilage, diarrhea, social functioning, emotional well-being, and constipation). Individual scale score was calculated as the average of the items in the scale. Individual scale score ranged from 0 to 3 for reflux, distention/bloating, fecal soilage, social functioning, and emotional well-being; 0 to 2 for diarrhea; and 0 to 2.5 for constipation. A total score was also calculated as the average of 6 of the 7 scales (omitting constipation) and ranged from 0 to 2.83. For individual and total scores 0 indicated better health and higher score indicates worse health.

Time frame:
Baseline, Weeks 4, 8, 12, and 16
Reported as:
Mean · units on a scale
University of California at Los Angeles (UCLA) Scleroderma Clinical Trial Consortium (SCTC) Gastrointestinal Trial (GIT) Questionnaire Scale Scores
units on a scalePirfenidone: 2-Week Titration GroupPirfenidone: 4-Week Titration Group
Reflux: Baseline (n=32, 31)0.3398 ± 0.340830.3347 ± 0.29117
Reflux: Week 4 (n=32, 31)0.4727 ± 0.432700.3548 ± 0.36529
Reflux: CFB Week 4 (n=32, 31)0.1328 ± 0.364690.0202 ± 0.26437
Reflux: Week 8 (n=32, 31)0.4660 ± 0.398810.4389 ± 0.46573
Reflux: CFB Week 8 (n=32, 31)0.1261 ± 0.368750.1043 ± 0.41664
Reflux: Week 12 (n=27, 30)0.4306 ± 0.410690.3417 ± 0.33142
Reflux: CFB Week 12 (n=27, 30)0.0880 ± 0.354940.0042 ± 0.26155
Reflux: Week 16 (n=25, 28)0.3950 ± 0.372700.3348 ± 0.39682
Reflux: CFB Week 16 (n=25, 28)0.0750 ± 0.25259-0.0045 ± 0.31820
Distention/Bloating: Baseline (n=32, 31)0.3984 ± 0.571000.5968 ± 0.58693
Distention/Bloating: Week 4 (n=32, 31)0.6406 ± 0.650490.4919 ± 0.65346
Distention/Bloating: CFB Week 4 (n=32, 31)0.2422 ± 0.41874-0.1048 ± 0.50734
Distention/Bloating: Week 8 (n=32,31)0.5703 ± 0.609850.4247 ± 0.57188
Distention/Bloating: CFB Week 8 (n=32, 31)0.1719 ± 0.47280-0.1720 ± 0.43245
Distention/Bloating: Week 12 (n=27, 30)0.5370 ± 0.706100.4250 ± 0.56152
Distention/Bloating: CFB Week 12 (n=27, 30)0.2130 ± 0.59929-0.1833 ± 0.47766
Distention/Bloating: Week 16 (n=25, 28)0.4800 ± 0.616270.4286 ± 0.48523
Distention/Bloating: CFB Week 16 (n=25, 28)0.1200 ± 0.45139-0.1518 ± 0.45307
Diarrhea: Baseline (n=32, 31)0.3281 ± 0.485420.2742 ± 0.48026
Diarrhea: Week 4 (n=32, 31)0.3125 ± 0.487750.2258 ± 0.48026
Diarrhea: CFB Week 4 (n=32, 31)-0.0156 ± 0.57480-0.0484 ± 0.43503
Diarrhea: Week 8 (n=32, 31)0.2813 ± 0.379680.3226 ± 0.55600
Diarrhea: CFB Week 8 (n=32, 31)-0.0469 ± 0.464190.0484 ± 0.58245
Diarrhea: Week 12 (n=27, 30)0.2778 ± 0.466850.2000 ± 0.48423
Diarrhea: CFB Week 12 (n=27, 30)-0.0556 ± 0.56045-0.0667 ± 0.58329
Diarrhea: Week 16 (n=25, 28)0.3400 ± 0.514780.2500 ± 0.51819
Diarrhea: CFB Week 16 (n=25, 28)0.0400 ± 0.57591-0.0179 ± 0.61587
Social Functioning: Baseline (n=32, 31)0.1250 ± 0.280780.1893 ± 0.43585
Social Functioning: Week 4 (n=32, 31)0.1563 ± 0.260720.1775 ± 0.27199
Social Functioning: CFB Week 4 (n=32, 31)0.0313 ± 0.25893-0.0118 ± 0.28143
Social Functioning: Week 8 (n=32, 31)0.1886 ± 0.313220.1936 ± 0.33647
Social Functioning: CFB Week 8 (n=32, 31)0.0635 ± 0.292330.0044 ± 0.37997
Social Functioning: Week 12 (n=27, 30)0.1173 ± 0.234880.1944 ± 0.30028
Social Functioning: CFB Week 12 (n=27, 30)0.0432 ± 0.25154-0.0011 ± 0.35730
Social Functioning: Week 16 (n=25, 28)0.0600 ± 0.135020.1667 ± 0.27596
Social Functioning: CFB Week 16 (n=25, 28)0.0133 ± 0.16607-0.0131 ± 0.40515
Emotional Wellbeing: Baseline (n=32, 31)0.0937 ± 0.260330.1326 ± 0.41910
Emotional Wellbeing: Week 4 (n=32, 30)0.0937 ± 0.216970.0778 ± 0.32516
Emotional Wellbeing: CFB Week 4 (n=32, 30)0.0000 ± 0.17831-0.0593 ± 0.14808
Emotional Wellbeing: Week 8 (n=32, 31)0.1181 ± 0.332730.0825 ± 0.29680
Emotional Wellbeing: CFB Week 8 (n=32, 31)0.0243 ± 0.11887-0.0502 ± 0.19846
Emotional Wellbeing: Week 12 (n=27, 30)0.0493 ± 0.131820.0852 ± 0.30979
Emotional Wellbeing: CFB Week 12 (n=27, 30)0.0123 ± 0.12055-0.0482 ± 0.14786
Emotional Wellbeing: Week 16 (n=25, 28)0.0266 ± 0.080300.0833 ± 0.39959
Emotional Wellbeing: CFB Week 16 (n=25, 28)0.0000 ± 0.10627-0.0357 ± 0.12851
Fecal Soilage: Baseline (n=32, 31)0.0313 ± 0.176780.1290 ± 0.42755
Fecal Soilage: Week 4 (n=32, 31)0.0313 ± 0.176780.1290 ± 0.42755
Fecal Soilage: CFB Week 4 (n=32, 31)0.0000 ± 0.000000.0000 ± 0.00000
Fecal Soilage: Week 8 (n=32, 31)0.0313 ± 0.176780.1613 ± 0.45437
Fecal Soilage: CFB Week 8 (n=32, 31)0.0000 ± 0.000000.0323 ± 0.17961
Fecal Soilage: Week 12 (n=27, 30)0.0370 ± 0.192450.1333 ± 0.43417
Fecal Soilage: CFB Week 12 (n=27, 30)0.0370 ± 0.192450.0000 ± 0.00000
Fecal Soilage: Week 16 (n=25, 28)0.0400 ± 0.200000.1071 ± 0.41627
Fecal Soilage: CFB Week 16 (n=25, 28)0.0400 ± 0.200000.0000 ± 0.00000
Constipation: Baseline (n=32, 31)0.2422 ± 0.408990.1694 ± 0.26130
Constipation: Week 4 (n=32, 30)0.2656 ± 0.341590.1500 ± 0.29066
Constipation: CFB Week 4 (n=32, 30)0.0234 ± 0.42293-0.0250 ± 0.30336
Constipation: Week 8 (n=32, 31)0.2578 ± 0.399010.1613 ± 0.46345
Constipation: CFB Week 8 (n=32, 31)0.0156 ± 0.25350-0.0081 ± 0.38989
Constipation: Week 12 (n=27, 30)0.2407 ± 0.389040.2111 ± 0.36075
Constipation: CFB Week 12 (n=27, 30)0.0370 ± 0.371480.0528 ± 0.49008
Constipation: Week 16 (n=25, 28)0.1800 ± 0.293330.1518 ± 0.27504
Constipation: CFB Week 16 (n=25, 28)0.0200 ± 0.37444-0.0179 ± 0.42453
Total Score: Baseline (n=32, 31)0.2194 ± 0.242620.2761 ± 0.32679
Total Score: Week 4 (n=32, 31)0.2845 ± 0.285280.2432 ± 0.31264
Total Score: CFB Week 4 (n=32, 31)0.0651 ± 0.20058-0.0330 ± 0.13591
Total Score: Week 8 (n=32, 31)0.2759 ± 0.261330.2706 ± 0.29132
Total Score: CFB Week 8 (n=32, 31)0.0564 ± 0.15749-0.0055 ± 0.20053
Total Score: Week 12 (n=27, 30)0.2416 ± 0.253290.2299 ± 0.27136
Total Score: CFB Week 12 (n=27, 30)0.0564 ± 0.16790-0.0492 ± 0.17709
Total Score: Week 16 (n=25, 28)0.2237 ± 0.197670.2284 ± 0.26906
Total Score: CFB Week 16 (n=25, 28)0.0481 ± 0.14444-0.0372 ± 0.20737

Adverse events

Collected over From baseline up to 28 days after the last dose of study drug (last dose = Week 16). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pirfenidone: 2-Week Titration Group—3/32 (9.4%)31/32 (96.9%)
Pirfenidone: 4-Week Titration Group—0/31 (0%)30/31 (96.8%)
Most frequent serious events
Most frequent serious events
EventPirfenidone: 2-Week Titration GroupPirfenidone: 4-Week Titration Group
BronchitisInfections and infestations1/320/31
Small intestinal obstructionGastrointestinal disorders1/320/31
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders1/320/31
Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders1/320/31
Most frequent other events
Showing 10 of 50
Most frequent other events
EventPirfenidone: 2-Week Titration GroupPirfenidone: 4-Week Titration Group
NauseaGastrointestinal disorders16/3215/31
HeadacheNervous system disorders14/3214/31
FatigueGeneral disorders13/3210/31
DiarrhoeaGastrointestinal disorders9/3210/31
CoughRespiratory, thoracic and mediastinal disorders10/324/31
VomitingGastrointestinal disorders9/329/31
RashSkin and subcutaneous tissue disorders8/325/31
Gastrooesophageal reflux diseaseGastrointestinal disorders6/327/31
AstheniaGeneral disorders2/325/31
DizzinessNervous system disorders5/325/31

Baseline characteristics

Safety population included all randomized participants who provided written informed consent and received at least one dose of study medication.

Age, Continuous
Age, Continuous(years)Pirfenidone: 2-Week Titration GroupPirfenidone: 4-Week Titration GroupTotal
Mean49.3 ± 12.0851.9 ± 12.5250.6 ± 12.27
Sex: Female, Male
Sex: Female, Male(Participants)Pirfenidone: 2-Week Titration GroupPirfenidone: 4-Week Titration GroupTotal
Female262652
Male6511
08

Study locations

22 sites
  • Mayo Clinic, Scottsdale
    Scottsdale, Arizona 85259, United States
  • University of California, Los Angeles
    Los Angeles, California 90095, United States
  • Stanford University School of Medicine
    Redwood City, California 94063, United States
  • University of California, San Francisco
    San Francisco, California 94143, United States
  • National Jewish Medical and Research Center
    Denver, Colorado 80206, United States
  • Georgetown University Hospital
    Washington, District of Columbia 20007, United States
  • Northwestern University, Chicago
    Chicago, Illinois 60611, United States
  • Boston University Medical Center
    Boston, Massachusetts 02118, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Hospital for Special Surgery
    New York, New York 10021, United States
  • Columbia University
    New York, New York 10032, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • University of Toledo
    Toledo, Ohio 43614, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15261, United States
  • Medical University South Carolina
    Charleston, South Carolina 29425, United States
  • University of Texas, Houston
    Houston, Texas 77030, United States
  • University of Utah
    Salt Lake City, Utah 84132, United States
  • St. Joseph's Healthcare
    Hamilton, Ontario L8N 142, Canada
  • Toronto General Hospital
    Toronto, Ontario M5T 3L9, Canada
  • Università di Torino
    Orbassano, Turin 10043, Italy
  • University of Florence
    Firenze, 50139, Italy
09

References and documents

Publications

  • Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980 May;23(5):581-90. doi: 10.1002/art.1780230510. PubMed 7378088 ↗
  • Khanna D, Albera C, Fischer A, Khalidi N, Raghu G, Chung L, Chen D, Schiopu E, Tagliaferri M, Seibold JR, Gorina E. An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial. J Rheumatol. 2016 Sep;43(9):1672-9. doi: 10.3899/jrheum.151322. Epub 2016 Jul 1. PubMed 27370878 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2013, a primary completion of Sep 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2015, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2013
First posted
Sep 2, 2013
Start
Oct 2013
Primary completionActual
Sep 2014
CompletionActual
Sep 2014
Results first posted
Sep 28, 2015
Last update
Aug 4, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01933334
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Sep 2, 2013
Start date
Oct 2013
Primary completion
Sep 2014
Completion
Sep 2014
Results posted
Sep 28, 2015
Last update
Aug 4, 2016

Study contacts

For additional information, call InterMune Medical Information Telephone: 1-888-486-6411
study chair · University of Cincinnati

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pirfenidone

Start the discussion